AR084152A1 - Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc - Google Patents
Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del sncInfo
- Publication number
- AR084152A1 AR084152A1 ARP110104533A ARP110104533A AR084152A1 AR 084152 A1 AR084152 A1 AR 084152A1 AR P110104533 A ARP110104533 A AR P110104533A AR P110104533 A ARP110104533 A AR P110104533A AR 084152 A1 AR084152 A1 AR 084152A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- lower alkyl
- haloalkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos para el tratamiento de enfermedades mentales y proliferativas.Reivindicación 1: Un compuesto de la fórmula (1) en la que: R1 es halógeno, alquilo inferior, haloalquilo inferior, hidroxialquilo inferior, alcoxi inferior, (alcoxi inferior)-alquilo inferior, -C(O)-NR9R10, arilo, heteroarilo o NR7R8, dichos arilo y heteroarilo pueden estar sustituidos por 1 - 3 sustituyentes elegidos con independencia entre el grupo formado por hidroxilo, halógeno, alquilo inferior, alcoxi inferior, (alcoxi inferior)-alquilo inferior, haloalquilo inferior y haloalcoxi inferior; R2 es hidrógeno, halógeno, alquilo inferior, haloalquilo inferior, hidroxialquilo inferior, alcoxi inferior o (alcoxi inferior)-alquilo inferior; R3 es hidrógeno, alquilo inferior, haloalquilo inferior, hidroxialquilo inferior, alcoxi inferior o (alcoxi inferior)-alquilo inferior; R4 es hidroxilo, alcoxi inferior o NR5R6; R5 y R6 son con independencia hidrógeno, alquilo inferior, haloalquilo inferior, hidroxialquilo inferior, (alcoxi inferior)-alquilo inferior, cicloalquilo o heterociclilo, o R5 y/o R6 son alquilo inferior sustituido por un sustituyente elegido entre el grupo formado por heteroarilo, (alquilo inferior)-heteroarilo y alcoxi inferior-C(O)- o R5 y R6, junto con el átomo de nitrógeno al que están unidos, forman un heterociclilo, biciclo-heterociclilo o espiro-heterociclilo, dicho heterociclilo puede estar sustituido por 1 - 3 sustituyentes elegidos con independencia entre el grupo formado por hidroxilo, halógeno, alquilo inferior, alcoxi inferior, (alcoxi inferior)-alquilo inferior, haloalquilo inferior y oxo; R7 y R8 son con independencia hidrógeno, alquilo inferior, haloalquilo inferior, hidroxialquilo inferior, (alcoxi inferior)-alquilo inferior o cicloalquilo o R7 y R8, junto con el átomo de nitrógeno al que están unidos, forman un heterociclilo opcionalmente sustituido por un sustituyente elegido entre el grupo formado por hidroxilo, halógeno y oxo; y R9 y R10 son con independencia hidrógeno, alquilo inferior, haloalquilo inferior, hidroxialquilo inferior o (alcoxi inferior)-alquilo inferior; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10194014 | 2010-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084152A1 true AR084152A1 (es) | 2013-04-24 |
Family
ID=45099086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104533A AR084152A1 (es) | 2010-12-07 | 2011-12-05 | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8349824B2 (es) |
| EP (1) | EP2649070B1 (es) |
| JP (1) | JP5932828B2 (es) |
| KR (1) | KR20130128426A (es) |
| CN (1) | CN103237803B (es) |
| AR (1) | AR084152A1 (es) |
| AU (1) | AU2011340685A1 (es) |
| BR (1) | BR112013013912A2 (es) |
| CA (1) | CA2816829C (es) |
| CL (1) | CL2013001591A1 (es) |
| CO (1) | CO6741154A2 (es) |
| CR (1) | CR20130239A (es) |
| CY (1) | CY1115863T1 (es) |
| DK (1) | DK2649070T3 (es) |
| EA (1) | EA022607B1 (es) |
| EC (1) | ECSP13012667A (es) |
| ES (1) | ES2520647T3 (es) |
| HR (1) | HRP20141200T1 (es) |
| IL (1) | IL225969A0 (es) |
| MA (1) | MA35086B1 (es) |
| MX (1) | MX2013006054A (es) |
| PE (1) | PE20140226A1 (es) |
| PL (1) | PL2649070T3 (es) |
| PT (1) | PT2649070E (es) |
| RS (1) | RS53677B1 (es) |
| SG (1) | SG190305A1 (es) |
| SI (1) | SI2649070T1 (es) |
| UA (1) | UA109037C2 (es) |
| WO (1) | WO2012076430A1 (es) |
| ZA (1) | ZA201303811B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043518A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| EP2757883B1 (en) * | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| CA2858778A1 (en) * | 2012-02-09 | 2013-08-15 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives |
| JP2016513083A (ja) * | 2013-01-31 | 2016-05-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 放射標識された化合物 |
| CN105189493B (zh) | 2013-02-27 | 2017-04-12 | 持田制药株式会社 | 新型吡唑衍生物 |
| WO2014177493A1 (en) * | 2013-04-30 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pd-CATALYZED COUPLING OF PYRAZOLE AMIDES |
| KR20160015211A (ko) * | 2013-05-31 | 2016-02-12 | 닛산 가가쿠 고교 가부시키 가이샤 | 복소환 아미드 화합물 |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| KR20170032329A (ko) | 2014-07-30 | 2017-03-22 | 모찌다 세이야쿠 가부시끼가이샤 | 피라졸 유도체의 제조 방법 |
| EP3176167A4 (en) * | 2014-07-30 | 2018-03-28 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| EP4161526A1 (en) * | 2020-06-05 | 2023-04-12 | Noema Pharma AG | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| WO2022162193A1 (en) | 2021-01-28 | 2022-08-04 | Noema Pharma Ag | Methods for the treatment of childhood-onset fluency disorder |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/ko not_active Application Discontinuation
- 2011-12-05 UA UAA201308329A patent/UA109037C2/uk unknown
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/da active
- 2011-12-05 CA CA2816829A patent/CA2816829C/en active Active
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/ja active Active
- 2011-12-05 AR ARP110104533A patent/AR084152A1/es unknown
- 2011-12-05 EA EA201390799A patent/EA022607B1/ru not_active IP Right Cessation
- 2011-12-05 SI SI201130309T patent/SI2649070T1/sl unknown
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/en active Application Filing
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/pt not_active Application Discontinuation
- 2011-12-05 PT PT117915439T patent/PT2649070E/pt unknown
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/en active Active
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/zh active Active
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/es active IP Right Grant
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/es not_active Application Discontinuation
- 2011-12-05 PL PL11791543T patent/PL2649070T3/pl unknown
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/es active Active
- 2011-12-05 RS RS20140574A patent/RS53677B1/en unknown
-
2013
- 2013-04-25 CO CO13105814A patent/CO6741154A2/es active IP Right Grant
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-05-22 CR CR20130239A patent/CR20130239A/es unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/es unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/es unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/fr unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/el unknown
- 2014-12-11 HR HRP20141200AT patent/HRP20141200T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR085987A1 (es) | Compuestos tri- y tetraciclicos pirazol[3,4-b]piridina como agentes antineoplasicos | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| CO6440596A2 (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero de rapamicina | |
| CU20120084A7 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
| AR091023A1 (es) | Inhibidores del nampt | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| UY29301A1 (es) | Derivados amida | |
| AR090994A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| PH12015500063A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| AR094100A1 (es) | DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS b2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR055344A1 (es) | Derivados de 1-oxoindano y 1-oxo-2,3-dihidroisoindol como inhibidores de p38, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la cinasa p38 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |